COPPER SPECIATION IN PROSTATE & BREAST CANCER

这个子项目是许多利用资源的研究子项目之一 由NIH/NCRR资助的中心拨款提供。子项目的主要支持 而子项目的主要调查员可能是由其他来源提供的， 包括其它NIH来源。 列出的子项目总成本可能 代表子项目使用的中心基础设施的估计数量， 而不是由NCRR赠款提供给子项目或子项目工作人员的直接资金。 我们已经进行了一系列的测量，使用新设计的弯曲劳厄分析仪的Cu K边缘XANES测量。分析仪由Al弯曲系统和不同厚度的Si（111）晶体组成，以便根据其最终应用提供更多的通量或更高的能量分辨率。我们使用的分析仪在能量分辨率方面表现出更好的性能，在Cu K线能量处接近10 eV。我们已经测量了一组标准样品组成的不同铜氧化态的铜化合物：Cu（I）和Cu（II）。使用硅漂移检测器和弯劳埃分析仪评价这些化合物。结果表明，Cu（I）化合物在8983 eV处具有非常强的前沿峰，而Cu（II）化合物没有该峰。即使在非常稀释的样品条件下，bent laue分析仪也能够识别差异。我们还评估了组织切片的Cu含量：正常组织和肿瘤组织。肿瘤数据表明Cu（II）物质可能存在于组织中，而正常组织数据表明Cu（II）物质的含量非常少或没有。将考虑其他补充技术对这些结果进行评价，以确认肿瘤组织切片中是否存在Cu（II）。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. We have performed a series of measurements using the newly designed Bent Laue analyzer for Cu K edge XANES measurements. The analyzers consist of an Al bender system and Si (111) crystal of different thicknesses in order to provide more flux or higher energy resolution depending on their final application. We have used the selected analyzer that shows better performance in term of energy resolution, near 10 eV at the Cu K¿ line energy. We have measured a set of standard samples consisting of Cu compounds of different Cu oxidation state: Cu(I) and Cu(II). These compounds were evaluated using a silicon drift detector and the bent laue analyzer. The results show that Cu(I) compounds have a very strong pre edge peak at 8983 eV where Cu(II) compounds do not have that peak. The bent laue analyzer was able to recognize the difference even under conditions of very diluted samples. We have also evaluated the Cu content of tissue sections: normal and tumor tissue. The tumor data indicates that Cu(II) species are potentially present in the tissue while the normal tissue data indicates very little or no content of Cu(II) species. These results will be evaluated considering other complementary technique to confirm the presence of Cu(II) in tumor tissue sections.